Childhood psychiatric disorders

Prescription Medication Usage During Pregnancy Has Unknown Effects on Fetal Development

Retrieved on: 
Tuesday, May 25, 2021
Psychiatric diagnosis, Medicine, Health, Psychiatry, Childhood psychiatric disorders, Learning disabilities, Amphetamine, Attention deficit hyperactivity disorder, Educational psychology, Asthma, Autism, Chronic condition

BOCA RATON, Fla., May 25, 2021 /PRNewswire/ --Medication usage during pregnancy has increased substantially over the last several decades.

Key Points: 
  • BOCA RATON, Fla., May 25, 2021 /PRNewswire/ --Medication usage during pregnancy has increased substantially over the last several decades.
  • Over a similar period of time, numerous chronic childhood illnesses have increased including neurodevelopmental delay, autism, asthma, ADHD and autoimmune illnesses.
  • "I see this extraordinary increase in the usage of medication during pregnancy coupled with increases in childhood illnesses, and I wonder if the two are connected.
  • Instead, what are obtained are animal reproductive toxicity data, which are inadequate, as animal species pharmacological data do not extrapolate well to humans.

Qelbree™ (viloxazine extended-release capsules), a New Non-Controlled Substance, Now Available for the Treatment of ADHD in Pediatric Patients 6-17 Years of Age

Retrieved on: 
Monday, May 24, 2021
Psychoactive drugs, Psychiatry, Attention deficit hyperactivity disorder, Amphetamine, Methylphenidate, Childhood psychiatric disorders, Educational psychology, Pemoline, Caregiver, Stimulant, Suicidal ideation, Attention deficit hyperactivity disorder management

Many of my patients and their caregivers seek non-stimulant options as we work together to develop a treatment regimen.

Key Points: 
  • Many of my patients and their caregivers seek non-stimulant options as we work together to develop a treatment regimen.
  • Supernus has developed a robust patient access program to support those who qualify for treatment.
  • As a non-controlled substance that has a unique profile of proven efficacy, safety, and tolerability, Qelbree provides patients living with ADHD a novel treatment option like no other ADHD medication.
  • Qelbree may increase suicidal thoughts and actions in some children with ADHD, especially within the first few months of treatment or when the dose is changed.

2021 Worldwide Attention Deficit Hyperactivity Disorder Industry - Understand Targeted Population for Research and Development - ResearchAndMarkets.com

Retrieved on: 
Monday, May 17, 2021
Health, General Health, Psychiatric diagnosis, Psychiatry, Medicine, Articles, Childhood psychiatric disorders, Attention deficit hyperactivity disorder, Amphetamine, Educational psychology, Attention deficit, Disease, Attention deficit hyperactivity disorder controversies, Bipolar disorder

b'The "Global Attention Deficit Hyperactivity Disorder Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nThe research report, Global Attention Deficit Hyperactivity Disorder Epidemiology and Patient Flow Analysis - 2021, provides Attention Deficit Hyperactivity Disorder epidemiology, demographics, and patient flow.

Key Points: 
  • b'The "Global Attention Deficit Hyperactivity Disorder Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nThe research report, Global Attention Deficit Hyperactivity Disorder Epidemiology and Patient Flow Analysis - 2021, provides Attention Deficit Hyperactivity Disorder epidemiology, demographics, and patient flow.
  • The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.\nThe research provides population data to characterize Attention Deficit Hyperactivity Disorder patients, history of the disease at the population level (Attention Deficit Hyperactivity Disorder prevalence, Attention Deficit Hyperactivity Disorder incidence) and at the clinical level (from diagnosis to treated patients).
  • It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.\nAttention Deficit Hyperactivity Disorder patient flow: Attention Deficit Hyperactivity Disorder prevalence, diagnosed, and drug-treated patients\nDemographics: Attention Deficit Hyperactivity Disorder patients by age group, gender\nThe data from this research will help executives:\nEstablish basis for Attention Deficit Hyperactivity Disorder market sizing, assessing market potential, and developing drug forecast models\nIdentify Attention Deficit Hyperactivity Disorder patients segments through age groups, gender, and disease sub-types\nEvaluate Attention Deficit Hyperactivity Disorder market opportunities, identify target patient population\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210517005615/en/\n'

Large Study Analyzes Two Different Classes of ADHD Drugs in Preschool-Age Children

Retrieved on: 
Tuesday, May 4, 2021
Health sciences, Childhood psychiatric disorders, Health, Psychiatry, Attention deficit hyperactivity disorder, Amphetamine, Methylphenidate, Medication, Pharmaceutical industry, Stimulant, Prescription drug

The researchers found that both classes of drugs have benefits, with differing side effects, suggesting that decisions on which class of drugs to prescribe should be made based on individual patient factors.

Key Points: 
  • The researchers found that both classes of drugs have benefits, with differing side effects, suggesting that decisions on which class of drugs to prescribe should be made based on individual patient factors.
  • In contrast, children aged 5 to younger than 6 prescribed were likely to continue using the medication for longer if they were prescribed a stimulant.
  • "Future research should seek to learn more about the use of these classes of drugs in preschool-age children so that we can prescribe the most effective therapy for each patient.
  • In addition, its unique family-centered care and public service programs have brought the 595-bed hospital recognition as a leading advocate for children and adolescents.

OWP Pharmaceuticals Announces Patent Application for the First-Ever Oral Liquid Formulation of Atomoxetine Hydrochloride for the Treatment of Attention Deficit Hyperactivity Disorder

Retrieved on: 
Thursday, April 22, 2021
Psychoactive drugs, Amphetamine, Psychiatry, Branches of biology, Childhood psychiatric disorders, Methylphenidate, Nootropics, Educational psychology, Attention deficit hyperactivity disorder, Atomoxetine

b"NAPERVILLE, Ill., April 22, 2021 (GLOBE NEWSWIRE) -- OWP Pharmaceuticals, Inc. is a privately held, commercial-stage neuroscience specialty pharmaceutical company, dedicated to developing and commercializing novel oral liquid formulations.

Key Points: 
  • b"NAPERVILLE, Ill., April 22, 2021 (GLOBE NEWSWIRE) -- OWP Pharmaceuticals, Inc. is a privately held, commercial-stage neuroscience specialty pharmaceutical company, dedicated to developing and commercializing novel oral liquid formulations.
  • OWP announced today that it has submitted for U.S. patent protection, for the first-ever oral suspension of atomoxetine hydrochloride.
  • The medication is widely prescribed by healthcare providers in psychiatry for ADHD, and it is indicated for treatment in children 6 years and older and adults.
  • Some individuals with ADHD also display difficulty regulating emotions or problems with executive function.

Supernus Announces FDA Approval of Qelbree™ (SPN-812) for the Treatment of ADHD

Retrieved on: 
Friday, April 2, 2021
Psychoactive drugs, Psychiatry, Amphetamine, Attention deficit hyperactivity disorder, Methylphenidate, Medicine, Childhood psychiatric disorders, Stimulant, Medication, Attention deficit hyperactivity disorder management, Attention deficit hyperactivity disorder controversies

Based on the efficacy demonstrated in the clinical program, we believe Qelbree offers a unique new alternative for the treatment of ADHD, said Jack A. Khattar, President and Chief Executive Officer of Supernus Pharmaceuticals.

Key Points: 
  • Based on the efficacy demonstrated in the clinical program, we believe Qelbree offers a unique new alternative for the treatment of ADHD, said Jack A. Khattar, President and Chief Executive Officer of Supernus Pharmaceuticals.
  • Qelbree provides prescribing physicians and patients living with ADHD a therapy that is not a controlled substance with proven efficacy and a tolerable safety profile.
  • This approval offers a novel once a day sprinkleable non-stimulant that can be a great option for children and adolescents with ADHD.
  • Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.

PureTech Founded Entity Akili Announces the Results of EndeavorRx™ Clinical Study in Pediatric ADHD Published in Nature Digital Medicine

Retrieved on: 
Friday, March 26, 2021
Oncology, FDA, Health, Clinical trials, Pharmaceutical, Biotechnology, Health sciences, Health, Articles, Clinical research, Design of experiments, Childhood psychiatric disorders, Amphetamine, Methylphenidate, Attention deficit hyperactivity disorder, The Lancet, Clinical trial, Randomized controlled trial, Akili, PureTech Health

The results have been published in the international peer-reviewed journal, Nature Digital Medicine.

Key Points: 
  • The results have been published in the international peer-reviewed journal, Nature Digital Medicine.
  • The results have been published in the international peer-reviewed journal, Nature Digital Medicine.
  • Building on the results of the STARS-ADHD pivotal study of EndeavorRx published in The Lancet Digital Health in February 2020, the STARS Adjunct study evaluated the safety and efficacy of EndeavorRx when used alone and alongside stimulants.
  • EndeavorRx has been studied in more than 600 children with ADHD across five clinical trials, including a large, multicenter prospective randomized controlled study.

Results of Akili’s EndeavorRx™ Clinical Study Published in Nature Digital Medicine, Demonstrate Improvements in Pediatric ADHD Impairments and Symptoms in Daily Life

Retrieved on: 
Friday, March 26, 2021
FDA, Health, Clinical trials, General Health, Pharmaceutical, Biotechnology, Psychology, Mind, Psychiatry, Attention deficit hyperactivity disorder, Childhood psychiatric disorders, Amphetamine, Methylphenidate, Psychiatric diagnosis, Attention deficit hyperactivity disorder management

Statistically significant improvement was demonstrated in all predetermined endpoints of the study, which included parent and clinician ratings of childrens ADHD symptoms and related impairments in daily life.

Key Points: 
  • Statistically significant improvement was demonstrated in all predetermined endpoints of the study, which included parent and clinician ratings of childrens ADHD symptoms and related impairments in daily life.
  • Standard clinician ratings of impairments and symptoms were measured, as well as ratings by parents of their children in daily life.
  • A change in the ADHD Impairment Rating Scale (IRS), a parent-reported assessment scale of ADHD- specific impairments observed in their childs day-to-day life, was the primary outcome measure of the study.
  • EndeavorRx has been studied in more than 600 children with ADHD across five clinical trials, including a large, multicenter prospective randomized controlled study.

The Stroud Foundation and CHADD Partner Up to Improve Virtual Learning for Children with ADHD

Retrieved on: 
Thursday, March 11, 2021
Attention deficit hyperactivity disorder, Childhood psychiatric disorders, Psychiatry, Abnormal psychology, Educational psychology, Psychiatric diagnosis, Amphetamine

Dr. Chronis-Tuscano and her team were selected through a competitive application process and thorough review by a committee of experts in ADHD representing both the Stroud Foundation and CHADD.

Key Points: 
  • Dr. Chronis-Tuscano and her team were selected through a competitive application process and thorough review by a committee of experts in ADHD representing both the Stroud Foundation and CHADD.
  • We're delighted to partner with CHADD and the experts at the University of Maryland to deliver high-yield, low-cost, real-world support for families of children with ADHD."
  • The Stroud Foundation is a tax-exempt public charity established in 2008 to honor the memory of pediatrician Dr. Frank Stroud.
  • The foundation is dedicated to improving the lives of children with learning differences and their families in the DC area, with a particular focus on children with attention-deficit/hyperactivity disorder (ADHD).

CHADD Honors Exceptional Contributions to the ADHD Community with Annual Awards

Retrieved on: 
Monday, March 8, 2021
Childhood psychiatric disorders, Psychiatry, Amphetamine, Attention deficit hyperactivity disorder, Educational psychology, Methylphenidate, Psychiatric diagnosis, United States Tennis Association, Abnormal psychology, Education

The 2020 Affiliate of the Year Award has been presented to CHADD Philadelphia in recognition of outstanding service to the community.

Key Points: 
  • The 2020 Affiliate of the Year Award has been presented to CHADD Philadelphia in recognition of outstanding service to the community.
  • Hall of Fame honorees are recognized for their leadership, innovation, and dedication to serving the ADHD community; their exceptional contributions to the field; and their steadfast commitment to CHADD.
  • The Lifetime Achievement Award is CHADD's highest honor, created to recognize sustained, fundamental, and outstanding contributions to the field of ADHD.
  • "We celebrate the exceptional contributions all of our 2020 award recipients have made to the ADHD community," said Robert Cattoi, Chief Executive Officer, CHADD.